| 摘要: |
| 目的分析多肿瘤标志物蛋白芯片中癌胚抗原(CEA)在各组人群中的表达以及其他指标的伴随情况,并探讨其可能的临床意义。方法收集近年我院可供分析的25 076例多肿瘤蛋白芯片检测结果,分析CEA在各组人群、常见肿瘤中的升高特点,以及CEA伴随其他检测指标升高在肿瘤中的分布情况。结果CEA升高在恶性肿瘤患者中明显高于良性病变患者及正常体检者(P＜0.01),以结直肠癌最高(41.85%),其次为胰腺癌(37.97%)和肺癌(37.16%)。在肿瘤患者中,CEA常伴随其他肿瘤标志物出现,以伴随CA125升高最为常见,其次为CA19-9和CA242。CEA/CA125伴随升高常见于胰腺癌(74.26%)、卵巢癌(69.57%)、肝细胞癌(62.13%)和肺癌(51.68%),CEA/CA19-9伴随升高常见于胰腺癌(77.23%)和肝细胞癌(72.34%),CEA/CA242伴随升高常见于胰腺癌(77.23%)和结直肠癌(57.61%)。CEA+CA19-9+CA242联合升高常见于胰腺癌(76.24%)、卵巢癌(52.17%)和结直肠癌(51.32%),CEA+CA19-9+CA242+CA125联合升高常见于胰腺癌(61.39%)。结论CEA在恶性肿瘤中广泛表达,但并非恶性肿瘤的特异性指标。CEA单项指标升高对结直肠癌、胰腺癌和肺癌的诊断具有较高价值, CEA联合CA125、CA19-9和CA242检测有利于提高胰腺癌、卵巢癌和结直肠癌的诊断阳性率。 |
| 关键词: 肿瘤标志物 多肿瘤蛋白芯片 癌胚抗原 糖类抗原 |
| DOI：10.3724/SP.J.1008.2012.00523 |
| 投稿时间：2011-10-30修订日期：2012-02-17 |
| 基金项目: |
|
| Multiple tumor marker chip for detection of serum carcinoembryonic antigen in various malignant tumors: results and diagnostic value analysis |
| DU Jia1,XIE Jia-yin1,YANG Xue-qin1,YANG Yu-xin1,LI Zeng-peng2,WANG Dong1* |
(1. Cancer Center, Institute of Field Surgery Research, Daping Hospital, Third Military Medical University, Chongqing 400042, China
2. Department of Pathology, Institute of Field Surgery Research, Daping Hosptital, Third Military Medical University, Chongqing 400042, China
*Corresponding author.) |
| Abstract: |
| ObjectiveTo analyze the expression of carcinoembryonic antigen (CEA) in various populations and the simultaneous expression of other markers using multiple tumor marker protein chip, and to discuss the possible clinical relevance. MethodsA total of 25 076 profiles of multiple tumor marker protein chip were collected in our hospital for analysis. The elevation of CEA in various populations and commonly-seen tumors was analyzed, and the combined elevation of CEA and other markers was also analyzed in tumors. ResultsElevation of CEA in patients with malignant tumors was significantly more than those in patients with benign lesions and normal controls (P<0.01), with the highest positive rate of CEA seen in the colorectal cancer (41.85%),followed by pancreatic cancer (37.97%) and lung carcinoma (37.16%). CEA was always accompanied by other markers in tumor patients, with the mostly seen elevated marker being CA125, followed by CA19-9 and CA242. The CEA/CA125 was often seen in pancreatic cancer (74.26%), ovarian cancer (69.57%), hepatocellular carcinoma (62.13%), and lung cancer(51.68%); CEA/CA19-9 was often seen in pancreatic cancer (77.23%) and hepatocellular carcinoma (72.34%); CEA/CA242 was often seen in pancreatic cancer(77.23%) and colorectal cancer(57.61%); CEA+CA19-9+CA242 was usually seen in pancreatic cancer(76.24%), ovarian cancer(52.17%), and colorectal cancer (51.32%); and CEA+CA19-9+CA242+CA125 was mostly seen in pancreatic cancer(61.39%). ConclusionCEA is widely expressed in malignant tumors, but it is not specific for malignant tumors. Single elevation of CEA has high value for diagnosis of colorectal cancer, pancreatic cancer, and lung carcinoma. CEA combined with CA125, CA19-9 or CA242 can help to improve the positive rate for diagnosis of pancreatic cancer, ovarian cancer and colorectal cancer. |
| Key words: tumor marker multiple tumor marker protein chip carcinoembryonic antigen carbohydrate antigen |
